Recent advances in antiretroviral treatment and prevention in HIV-infected patients

Current Opinion in HIV and AIDS

Volumn 6, Issue SUPPL. 1, 2011, Pages

  Maltêz, Fernando ^a   Doroana, Manuela ^b   Branco, Teresa ^c   Valente, Cristina ^d  

^a HOSPITAL CURRY CABRAL   (Portugal)

^b H Santa Maria   (Portugal)

^c Medical Genetics Service   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

antiretrovirals; HIV; strategies; vaccination

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; BEVIRIMAT; COBICISTAT; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FAMOTIDINE; FOSAMPRENAVIR PLUS RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LOPINAVIR PLUS RITONAVIR; OMEPRAZOLE; PLACEBO; RALTEGRAVIR; RIFAMPICIN; RILPIVIRINE; RITONAVIR PLUS TIPRANAVIR; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MENTAL DISEASE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEIZURE; VACCINATION; VIRUS RESISTANCE; VOMITING;

AIDS VACCINES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS;

EID: 83655196759     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/01.COH.0000410238.80894.81     Document Type: Review

References (86)

1. WHO/UNAIDS/UNICEF. 2009 [cited 2010 Aug 4]; Available from: http:// data.unaids.org/pub/report/2009.
2. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-1503.
3. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis 2010; 50 (Suppl 3):S85-S95.
4. Mehellou Y, De Clercq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem 2010; 53:521-538.
5. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive patients: week 96 results of a phase IIb randomized trial. AIDS 2010; 24:55-65.
6. Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278-a novel NNRTI-in treatment-naive HIV-1-infected subjects. AIDS 2006; 20:1721-1726. (Pubitemid 44299363)
7. Cohen C, Molina J-M, Cahn P, et al. Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients. Journal of the International AIDS Society 2010, 13(Suppl 4):O48. Published: 8 November 2010.
8. Baert L, vant Klooster G, Dries W, et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 2009; 72:502-508.
9. Hoetelmans R, Kestens D, Marien K, et al. Effect of food and multiple dose pharmacokinetics of TMC278 as an oral tablet formulation [abstract no. TuPe3.1B10]. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005; Rio de Janeiro.
10. Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 2009; 48:211-241.
11. Crauwels HM, van Heeswijk RPG, Kestens D, et al. The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). J Int AIDS Soc 2008; 11 Suppl.1: 239.
12. Van Heeswijk R, Hoetelmans R, Kestens D, et al. The pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteers [abstract no. TUPDB01]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2007; Sydney.
13. Rimsky LT, Azijn H, Tirry I, et al. In vitro resistance profile of TMC278, a nextgeneration NNRTI; evidence of a higher genetic barrier and a more robust resistance profile than first generation NNRTIs. 18th International HIV Drug Resistance Workshop; 2009; Florida.
14. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010; 201:814-822.
15. Gilead Sciences. Mulitcenter, randomized, double-blind, double-dummy, phase study of the safety and efficacy of ritonavir-boosted elvitegravir (EVG/r) versus raltegravir (RAL) [ClinicalTrials.gov identifier NCT00708162]. US National Institutes of Health, ClinicalTrials.gov. [cited 2011 May 2] Available from http://www.clinicaltrials.gov
16. Gilead Sciences. Phase 3 study of the safety and efficacy of ritonavir-boosted elvitegravir (EVG/r) versus raltegravir (RAL) [ClinicalTrials.gov identifier NCT00707733]. US National Institutes of Health, ClinicalTrials.gov. [cited 2011 May 2]; Available from: http://www. clinicaltrials.gov
17. Cohen C, Shamblaw D, Ruane P, et al. Single-tablet, fixed-dose regimen of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster. 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco.
18. Schafer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. Ann Pharmacother 2010; 44:145-156.
19. Ramanathan S, Mathias AA, Shen G, et al. Lack of clinically relevant drugdrug interaction between ritonavir-boosted GS-9137 (elvitegravir) and fosamprenavir/r [abstract]. 4th International AIDS Society Conference; 2007; Sydney.
20. Mathias A, Ramanathan S, Hinkle J, et al. Effect of atazanavir/r on the steadystate pharmacokinetics of elvitegravir [abstract no. A-1417]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago.
21. Mathias A, West S, Enejosa J, Kearney B. A pharmacokinetic interaction between lopinavir/r and elvitegravir [abstract no. A-1418]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago.
22. Ramanathan S, Abel S, Tweedy S, et al. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. J Acquir Immune Defic Syndr 2010; 53:209-214.
23. German PI, West S, Hui J, Kearney BP. Pharmacokinetic interaction between elvitegravir/ritonavir and dose-adjusted rifabutin [abstract no. P19]. 9th International Workshop on Clinical Pharmacology of HIV Therapy; 2008; New Orleans, LA.
24. Ramanathan S, Hinkle J, Enejosa J, Kearney B. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid-reducing agents [abstract no. 69]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007; Budapest.
25. McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137) [abstract no. 9]. Antiviral Therapy 2007; 12 (Suppl. 1):S11.
26. Koelsch KK, Cooper DA. Integrase inhibitors in salvage therapy regimens for HIV-1 infection. Curr Opin HIV AIDS 2009; 4:518-523.
27. Suleiman J, Zingman BS, Diaz RS, et al. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J Infect Dis 2010; 201:590-599.
28. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196:304-312. (Pubitemid 47047471)
29. Gulick R, Su Z, Flexner C, et al. ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects week results [abstract]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention 2007; Sydney.
30. McCarthy MC, Suleiman J, Diaz R, et al. Vicriviroc long-term safety and efficacy: 96-week results from the VICTOR-E1 study [poster no. H-923]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009; San Francisco.
31. Gathe J, Diaz R, Fatkenheuer G, et al. Phase 3 trials of vicirviroc in treatmentexperienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone. 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco.
32. Schering-Plough. Efficacy and safety of vicriviroc in HIV-infected treatmentnaive subjects (study P04875AM5) [ClinicalTrials.gov identifier NCT00551018]. US National Institutes of Health, ClinicalTrials.gov. [cited 2011 May 2]; Available from: http://www.clinicaltrials.gov
33. Landovitz RJ, Angel JB, Hoffmann C, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008; 198:1113-1122.
34. Schurmann D, Fatkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21:1293-1299. (Pubitemid 46883483)
35. Dau B, Holodniy M. Novel targets for antiretroviral therapy: clinical progress to date. Drugs 2009; 69:31-50.
36. Schering Plough Research Institute. Investigators brochure update (SCH417690): summary of important changes 04 Aug 2009. Schering Plough Research Institute, New Jersey, USA.
37. Smith PF, Ogundele A, Forrest A, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 2007; 51:3574-3581. (Pubitemid 47519346)
38. Lalezari J, McCallister S, Gigliotti M, et al. A phase 2 safety and efficacy study of bevirimat (BVM) in heavily treatment experienced HIV patients identifies the target phase 3 study profile [abstract no. H-891]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America - a joint meeting; 2008; Washington, DC.
39. Bloch M, Bodsworth N, Mather G, et al. Efficacy, safety and pharmacokinetics of MPC-4326 (bevirimat dimeglumine) 200mg BID and 300mg BID monotherapy administered for 14 days in subjects with HIV-1 infection [slide presentation]. 2009 [cited 2011 May 2]; Available from: http://www.myriad pharma.com/about-us/scientific-presentations
40. Stoddart CA, Joshi P, Sloan B, et al. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One 2007; 2:e1251.
41. Gazzard BG. British HIV Association Guidelines for the treatment of HIV-1- infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
42. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333.
43. McKinnon JE, Mellors JW, Swindells S. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther 2009; 14:1-12.
44. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989. (Pubitemid 43867699)
45. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-465. (Pubitemid 44142768)
46. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
47. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861. (Pubitemid 38917251)
48. Khanlou H, Yeh V, Guyer B, Farthing C. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 2005; 19:135-140. (Pubitemid 40478291)
49. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921-1930. (Pubitemid 41681890)
50. Perez-Elias MJ, Moreno A, Moreno S, et al. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. HIV Clin Trials 2005; 6:312-319. (Pubitemid 43336965)
51. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-393.
52. Bierman WF, van Agtmael MA, Nijhuis M, et al. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23:279-291.
53. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 1998; 339:1269-1276. (Pubitemid 28496192)
54. Mallolas J, Pich J, Penaranda M, et al. Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults. AIDS 2008; 22:377-384.
55. Markowitz M, Hill-Zabala C, Lang J, et al. Induction with abacavir/lamivudine/ zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39:257-264. (Pubitemid 40923204)
56. Katlama C, Fenske S,Gazzard B, et al. TRIZAL study: switching fromsuccessful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet weeks efficacy, safety and adherence results. HIV Med 2003; 4:79-86. (Pubitemid 36582289)
57. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185:1251-1260. (Pubitemid 34439132)
58. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998; 339:1261-1268. (Pubitemid 28496191)
59. Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007; 44:417-422. (Pubitemid 46555376)
60. Wilkin TJ, McKinnon JE, DiRienzo AG, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 2009; 199:866-871.
61. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavirritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-814. (Pubitemid 44223104)
62. Arribas J, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir monotherapy shows non-inferior efficacy to standard HAART for patients with HIV RNA < 50 copies/mL at baseline [abstract]. 5th International AIDS Society Conference on HIV Pathogenesis Treatment and Prevention 2009; Cape Town, South Africa
63. Katlama C, Valentin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24:2365-2374.
64. Sahali S, Chaix ML, Delfraissy JF, Ghosn J. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection. AIDS Rev 2008; 10:4-14. (Pubitemid 351524047)
65. Ripamonti D, Maggiolo F, Bombana E, et al. Efficacy, safety and tolerability of dual therapy with raltegravir and atazanavir in antiretroviral experienced patients [abstract no. MOPEB067]. 5th International AIDS Society Conference on HIV Pathogenesis and Treatment; 2009; Cape Town, South Africa.
66. Reynes J, Lawal A, Pulido F, et al. Lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) demonstrated similar antiviral efficacy and safety as LPV/r combined with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment- naive HIV-1-infected subjects: PROGRESS 48 week results. 18th International AIDS Conference; 2010; Vienna.
67. National Institute of Allergy and Infectious Diseases. Safety and effectiveness of raltegravir and darunavir/ritonavir in treatment-naive HIV-infected adults [ClinicalTrials.gov identifier NCT00830804]. US National Institutes of Health, ClinicalTrials.gov. [cited 2011 May 2] Available from http://www.clinical trials.gov
68. Kozal MJ, Lupo S, DeJesus E, et al. The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300mg BID plus raltegravir (RAL) 400mg BID (ATVRAL) in treatment-naive HIV-infected subjects. 18th International AIDS Conference; 2010; Vienna.
69. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455:613-619.
70. Puls RL, Emery S. Therapeutic vaccination against HIV: current progress and future possibilities. Clin Sci (Lond) 2006; 110:59-71. (Pubitemid 43059045)
71. Robinson HL. HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 2007; 82:686-693.
72. Kallings LO. The first postmodern pandemic: 25 years of HIV/AIDS. J Intern Med 2008; 263:218-243. (Pubitemid 351207350)
73. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV- 1. Nature 2003; 422:307-312.
74. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393:648-659. (Pubitemid 28289647)
75. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655. (Pubitemid 24183063)
76. Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8 cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-6110. (Pubitemid 24258634)
77. Wille-Reece U, Flynn BJ, Lore K, et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006; 203:1249-1258. (Pubitemid 43736594)
78. Schoenly KA, Weiner DB. Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol 2008; 82:3166-3180. (Pubitemid 351429898)
79. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006; 24:4062-4081.
80. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
81. Girard MP, Bansal GP. HIV/AIDS vaccines: a need for new concepts? Int Rev Immunol 2008; 27:447-471.
82. Boberg A, Isaguliants M. Vaccination against drug resistance in HIV infection. Expert Rev Vaccines 2008; 7:131-145. (Pubitemid 351357970)
83. Pitisuttithum P. HIV vaccine research in Thailand: lessons learned. Expert Rev Vaccines 2008; 7:311-317. (Pubitemid 351520019)
84. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
85. GrayGon behalf of HVTN 503 (Phambili). Why we unblinded Phambili. HVTN full group meeting, Seattle. 2007 [cited 2011 May 2]. Available from http:// www.hvtn.org/fgm/1107slides/Gray.pdf.
86. Hurwitz JL, Zhan X, Brown SA, et al. HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail. Front Biosci 2008; 13:609-620. (Pubitemid 351599771)